LENZ Therapeutics to Participate in Upcoming Investor Conferences
LENZ Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or "LENZ" or the "Company"), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences:
洛杉矶，2024年11月12日（环球新闻社） - LENZ Therapeutics，Inc.（纳斯达克：LENZ或“ LENZ”或“公司”），一家处于临床前阶段的生物药公司，专注于开发和商业化第一款也是唯一的以乙硫胺碱为基础的眼用滴眼液，用于改善老花眼的近视能力，今天宣布公司管理层将参加以下即将举行的投资者会议：
Jefferies London Healthcare Conference (London, UK)
Management will participate in one-on-one meetings from Tuesday, November 19th through Thursday, November 21st, 2024.
杰富瑞伦敦健康医疗大会（伦敦，英国）
管理层将参加从2024年11月19日星期二至11月21日星期四的一对一会议。
Piper Sandler 36th Annual Healthcare Conference (New York, NY)
Management is scheduled to participate in a fireside chat on Tuesday, December 3rd, 2024 at 3:30pm ET and will participate in one-on-one meetings.
派杰投资第36届年度医疗保健大会（纽约，纽约州）
管理层计划于2024年12月3日星期二下午3:30参加炉边聊天，并将参加一对一会议。
7th Annual Evercore HealthCONx Conference (Coral Gables, FL)
Management is scheduled to participate in a fireside chat on Wednesday, December 4th, 2024 at 7:30 AM ET and will participate in one-on-one meetings.
第七届evercore HealthCONx大会（佛罗里达州科勒盖布斯）
管理层计划于2024年12月4日星期三上午7:30参与炉边聊天，并将参加一对一会议。
Citi 2024 Global Healthcare Conference (Miami, FL)
Management is scheduled to participate in a panel discussion titled, "Eyes Wide Open on Ophthalmology" on Thursday, December 5, 2024 at 1:45 PM ET and will participate in one-on-one meetings.
Citi 2024全球医疗保健大会（佛罗里达州迈阿密）
管理层计划于2024年12月5日星期四下午1:45参与名为“眼科医疗保健方面的明智选择”的专题讨论，并将参加一对一会议。
A live audio webcast of the Piper Sandler Healthcare Conference fireside chat can be accessed here and on the LENZ Therapeutics website at in the Investors & Media section. A replay of the webcast will be available on the Company's website for 12 months following the event.
Piper Sandler医疗保健大会炉边聊天的现场音频网络广播可在LENZ Therapeutics网站投资者与媒体部分进行访问。 派杰投资将在活动结束后的12个月内在公司网站上提供网络广播的重播。
About LENZ Therapeutics
LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ's product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for "all eyes, all day". LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.
关于LENZ Therapeutics
LENZ Therapeutics是一家面向未商业化的生物制药公司，专注于开发和商业化第一款也是唯一一款基于乙胆碱的眼药水，以改善患老视症的患者的近视能力。LENZ的药物候选品LNZ100是一种无防腐剂、一次性使用的每日一次眼药水，含有乙胆碱。LNZ100在注册启动阶段3的CLARITY研究中进行评估，作为老视症治疗的潜在疗法，这是一种影响全球约18亿人和美国约12800万人的控件。美国食品药品监督管理局（FDA）已经为LNZ100指定了处方药用户费法案（PDUFA）的目标行动日期为2025年8月8日。LENZ致力于商业化一种理想的药物老视症解决方案，提升了"全球货币，全天候"的视力。LENZ总部位于加利福尼亚州圣地亚哥。欲了解更多信息，请访问：LENZ-Tx.com。
Contacts:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
联系人：
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
